News | February 23, 2024
Moderna posts Q4 2023 revenue at US$ 2.8 billion
Net product sales in the fourth quarter of 2023 include the recognition of $0.6 billion from deferred revenue, related to Gavi, the Vaccine Alliance
Net product sales in the fourth quarter of 2023 include the recognition of $0.6 billion from deferred revenue, related to Gavi, the Vaccine Alliance
The acquisition enriches AstraZeneca’s growing pipeline of cell therapies with GC012F
The acquisition of Healint aligns with Aptar Digital Health’s strategy to broaden its portfolio in neurology and strengthen its global footprint for digital health deployment
We are achieving the target of developed India by making our young children healthy today
Project achieves 30% reduction in hospital acquired infections and 24% reduction in the incidence of multi-drug resistant organisms
The fast pace of construction of AIIMS Jammu whose foundation stone laying to inauguration took only 5 years highlights the commitment of the Government
The acquisition will build on AstraZeneca’s expertise in respiratory syncytial virus
The launch of a DGCA Type Approved Logistics Drone facilitates critical medical deliveries to remote regions
VELSIPITY is the first and only oral advanced ulcerative colitis therapy approved for use in patients 16 years of age or older in the EU
Sustainability is integral to Biocon's business purpose
Subscribe To Our Newsletter & Stay Updated
